UK's Oxford BioMedica, Nycomed Amersham in R&D deal

20 March 2000 19:58  [Source: ICIS news]

LONDON (CNI)--Oxford BioMedica, the UK biotechnology company, announced Monday it has licensed Anglo-Norwegian firm Nycomed Amersham to use its technology to develop imaging systems for tumour diagnosis.

Under the terms of the licence, financial details of which were not disclosed, Oxford BioMedica will supply Nycomed, a life sciences and imaging firm, with antibody fragments to its tumour-associated antigen, OBA-1.

Nycomed will investigate the use of radiolabelled versions of the antibody fragments as novel imaging agents.

Oxford BioMedica said that such imaging agents could be applicable on a variety of cancers as the OBA-1 marker is known to exist in most human tumours.

By: Patrick Reynolds
+44 208 652 3214

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly